KRMN just delivered its first Q1 print as a public company — and the reaction sums up the tension that has hung over the stock all month: the top line impressed, the bottom line disappointed, and the Street is resetting its numbers lower.
The headline print landed after Tuesday's close. Revenue of $151.2M narrowly beat the $150.1M consensus. Adjusted EPS of $0.11 missed the $0.12 estimate. The company raised full-year 2026 sales guidance to $720M–$735M from $715M–$730M, nudging the midpoint just above analyst estimates. It also announced contingent demand commitments from four unnamed space and defense clients worth over $1B across four to seven years. The stock had fallen 24% over the past month heading into the print, so a 6% rebound on the day of results reflected the market's relief rather than outright enthusiasm. It still ended the week fractionally lower, at $62.48.
Positioning tells a more cautious story. Short interest has climbed 4.2% over the past week to reach roughly 7% of the free float — and is up 8% over the past month, making it one of the steadier short builds in the sector. At just over nine million shares short, this is a measured accumulation rather than an aggressive raid, but the direction has been consistent. Cost to borrow is not yet flashing stress, running at 0.51% annualised, though that rate is up 18% over the week. Availability is well above 200% of short interest, meaning the lending pool remains open and there is no squeeze dynamic in play. The ORTEX short score is 60.7 — elevated but not extreme — reflecting the combination of rising shorts and a stock that has given back meaningful ground from its highs.
Options traders edged more defensive on the day of results. The put/call ratio moved to 1.12, roughly 1.6 standard deviations above its 20-day mean of 1.00 — the most skewed reading in recent weeks. That follows a stretch where the PCR had drifted back toward neutral after sitting above 1.1 in mid-April. With the earnings catalyst now cleared, whether options positioning normalises in coming sessions will be a useful read on how much residual nervousness lingers.
The analyst community came out of Tuesday's print divided. Evercore ISI's Amit Daryanani, one of the more closely watched voices on the name, maintained his Outperform but cut his price target to $100 from $125 — a significant 20% reduction that signals tempered confidence in the path to profitability even as the revenue trajectory holds. Against that, the broader analyst stack remains constructive. Multiple Buy-rated firms have targets between $122 and $135, a cluster set earlier in the year when the stock was trading nearer those levels. The mean target is now $112, implying nearly 80% upside to Tuesday's close — a gap that reflects either deep value or targets that haven't yet caught down to where the stock is trading. On valuation, the EV/EBITDA multiple is running at 37.3x, up slightly on the week. The P/E has compressed sharply, down 37 turns over the past month as the stock re-rated lower. EPS momentum factor scores are constructive at the 71st percentile on both a 30- and 90-day basis, while the 12-month forward EPS growth rank sits at the 80th percentile — the fundamental trajectory that bulls are anchoring on.
Institutional flows into the name have been notable since its listing. Vanguard and Fidelity both added large positions in Q1, with Vanguard reporting 9.3M shares as of March 31 and Fidelity at 8.4M — both sizeable relative to the float. BlackRock, Invesco, Van Eck, and State Street all added shares through April. That passive and active institutional accumulation provides a foundation, though it also means the register carries limited near-term flexibility if earnings disappointments continue.
Peer performance this week offers context. MRCY rallied over 11%, DRS gained nearly 8%, and RCAT added 5.8% — all outperforming KRMN's flat week. KTOS fell 3.3%. The broad defense complex found buyers, driven partly by macro tailwinds around government spending and space-related demand, which makes KRMN's relative underperformance heading into the print more visible by contrast.
The next pivot is whether the $1B-plus contingent demand pipeline translates into contracted backlog — and whether the EPS shortfall proves to be a timing issue or something more structural. That distinction will define the tone of analyst revisions over the next few weeks.
See the live data behind this article on ORTEX.
Open KRMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
